Otsuka Holdings (4578.T) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

4578.T · Stock Price

JPY 11,025+4,330 (+64.68%)

Market Cap: $37.1B

Historical price data

Market Cap: $37.1BFounded: 1964Employees: Approximately 47,000HQ: Tokyo, Japan

Sector Ranking#2 in Small Molecule Drugs #1 in Neuroscience & CNS

Overview

Otsuka Holdings is a multinational healthcare leader founded on the mission 'Otsuka-people creating new products for better health worldwide.' It has achieved global prominence through flagship CNS drugs, a strategic stake in Lundbeck, and blockbuster nutraceutical brands like Pocari Sweat. The company's strategy is built on a diversified four-pillar business model—pharmaceuticals, nutraceuticals, medical devices, and chemicals—driven by a unique culture of creativity ('Souzoususei') and evidence-based validation ('Jisshou').

Central Nervous SystemPsychiatryNeurologyOncologyNephrologyCardiovascular

Technology Platform

Deep expertise in CNS neuropharmacology and innovative drug delivery systems, including orodispersible tablets and long-acting injectable formulations, complemented by functional beverage science.

Funding History

1

IPOUndisclosedUndisclosedDec 15, 2010

FDA Approved Drugs

4

VOYXACTBLANov 25, 2025

ABILIFY MAINTENA KITNDAFeb 28, 2013

NUEDEXTANDAOct 29, 2010

Opportunities

Significant near-term opportunity with the potential expansion of Rexulti into Alzheimer's disease agitation and the global rollout of the 2-month Abilify injectable.

Long-term growth is supported by a diversified pipeline in high-need CNS and oncology areas, and the expanding global health & wellness trend for its nutraceutical division.

Risk Factors

High dependence on key patented products facing future generic competition.

Inherent risk and high failure rate in CNS drug development.

Exposure to global pharmaceutical pricing pressures and regulatory hurdles across multiple markets.

Competitive Landscape

Competes with global pharma giants (J&J, AbbVie) in CNS, specialized biopharma (Lundbeck), and large consumer goods companies in nutraceuticals. Differentiation is achieved through deep CNS expertise, innovative formulation technologies, and a unique diversified business model blending pharmaceuticals and consumer health.